Transcript Influenza - Thomson Reuters

THOMSON REUTERS INTEGRITYSM
INFLUENZA A: A New Challenging Opportunity for Market Impact
1
THOMSON REUTERS INTEGRITY:
SUMMARY
This use case will focus on Influenza A and, specifically on Oseltamivir Phosphate
(Tamiflu®), a currently available drug being used to treat this challenging disease.
It will also demonstrate how to analyze current synthetic approaches to this compound,
looking for new opportunities for chemical intermediate and reagent producers.
THOMSON REUTERS INTEGRITY:
INFLUENZA
Influenza is highly contagious acute viral infection of the respiratory tract causing the
flu, a disease with symptoms that include fever, myalgia, headache, malaise, cough,
sore throat, rhinitis and other common cold-like symptoms
Influenza A (H1N1) and the 2009 Influenza Pandemic
Swine influenza (swine flu) is a respiratory disease of pigs caused by type A influenza
virus that regularly causes outbreaks of influenza in pigs. The incidence of swine flu in
humans is normally quite low. In spring 2009, however, an outbreak occurred in
Mexico and spread quickly to parts of the U.S., with other travel-related cases
reported soon thereafter in various European and Asian countries.
A new strain of the H1N1 virus is responsible for these cases. The 2009 influenza
pandemic has spread internationally with unprecedented speed. The World Health
Organization reports that as of November 22, 2009, more than 622,480 laboratoryconfirmed cases of influenza A (H1N1) infection, including at least 7,826 deaths, have
been officially registered in at least 207 countries worldwide.
The influenza A (H1N1) virus is susceptible to treatment with the neuraminidase
inhibitors oseltamivir (Tamiflu) and zanamivir (Relenza), but not to amantadine or
rimantadine.
THOMSON REUTERS INTEGRITY:
DISEASE BRIEFING: INFLUENZA
Select the Disease
Briefings Knowledge
Area from the pull down
menu on the Integrity
home page
THOMSON REUTERS INTEGRITY:
DISEASE BRIEFING: INFLUENZA
Select the Influenza
disease briefing from the
left hand quick access
menu or using the
Disease Briefing search
field where the browse
Index can be used to
find and select terms.
THOMSON REUTERS INTEGRITY:
DISEASE BRIEFING: INFLUENZA
In the Facts About
Influenza, specific
information can be found,
for example, click
Special Focus:
Influenza A (H1N1)
and 2009 Influenza
Pandemic
THOMSON REUTERS INTEGRITY:
DISEASE BRIEFING: INFLUENZA
This provides information
on the H1N1 virus,
Interspecies
Transmission, Gene
Reassortment and other
relevant information…
THOMSON REUTERS INTEGRITY:
DISEASE BRIEFING: INFLUENZA
… including current drug
treatment and
vaccines available.
To find more information
on the cited products, for
example, Tamiflu®, go to
the Drugs & Biologics
Knowledge Area by
selecting from the drop
down menu at the top
left hand side of the
page.
THOMSON REUTERS INTEGRITY:
PRODUCT RECORD
Once in this Knowledge
Area, select the Drug
Name search field. Open
the browse Index and
type in a partial term in
the lookup box. Click
Lookup and then select
the name and then OK to
automatically copy it back
into the search form.
Click Start or hit return
to launch the search
THOMSON REUTERS INTEGRITY:
PRODUCT RECORD
The Product Record is
retrieved. The Full Record
display provides general
and chemical
information about the
product…
THOMSON REUTERS INTEGRITY:
PRODUCT RECORD
… a Product Summary,
a Development Status
Summary and links to
Related Information in
the other Knowledge
Areas of Integrity.
THOMSON REUTERS INTEGRITY:
PRODUCT RECORD
Click the Sales button…
THOMSON REUTERS INTEGRITY:
PRODUCT RECORD: Sales
…to open a pop-up
window with sales
figures. Due to the
Influenza pandemic, the
sales for this product
have grown substantially
in 2009. This makes the
compound interesting
selection for the
development of improved
chemical syntheses or
sales of intermediates.
THOMSON REUTERS INTEGRITY:
PRODUCT RECORD: Related Information
Click on the Related
Information link to move
to the Organic
Synthesis Knowledge
Area where synthetic
schemes related to this
product can be displayed.
THOMSON REUTERS INTEGRITY:
ORGANIC SYNTHESIS SCHEMES
The related schemes
include a synthesis text,
intermediates and
reagents lists, sources
(patents and references)
and Related Information
in other Knowledge
Areas.
From the synthesis
schemes for Tamiflu®,
view the intermediates by
going to Options and
selecting Intermediate
List.
THOMSON REUTERS INTEGRITY:
ORGANIC SYNTHESIS INTERMEDIATE LIST
A full list of related
intermediates is shown
with their structure,
molecular weight,
molecular formula and
Standard InChIKey.
Select and click on any
intermediate of interest
to pull out access further
information...
THOMSON REUTERS INTEGRITY:
ORGANIC SYNTHESIS INTERMEDIATE FULL RECORD
… including the chemical
name, supplier
information and Related
information in other
Knowledge Areas. Click
Show All to view
suppliers. Click the
Drugs & Biologics
Related Information
button to view products
currently synthesized
using this intermediate.
THOMSON REUTERS INTEGRITY:
ALL RELATED INFORMATION VIA QUICK SEARCH
A list of records appears
showing that this
intermediate can be
supplied not only for the
synthesis of Tamiflu® but
also in other 3 products,
two of which are under
active development in
early phases.
THOMSON REUTERS INTEGRITY:
SUPPORT/HELP
For questions about
Integrity’s contents
or features, send a
message via the
Help Request /
Suggestion Form
in Integrity or
contact
integritysupport
@prous.com